Trametinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the evidence pack's own annotations to select the reporting focus: TxGNN's #1-ranked hit (choroideremia, 99.31%) is explicitly flagged in its own repurposing_rationale as likely model noise (no mechanistic link, zero trials, zero literature, recommendation = Hold). Building the whole report around a self-identified false positive would be misleading, so I'm reporting on the highest-scoring prediction that actually carries mechanistic and evidentiary support: non-cutaneous melanoma (rank 2, L1/S3, Proceed with Guardrails).
Trametinib: From BRAF-Mutant Cutaneous Melanoma to Non-Cutaneous Melanoma
Note on model output: TxGNN's single highest-scoring prediction for trametinib was choroideremia (score 99.31%). The evidence pack's own analysis judged this a likely false positive — no mechanistic link to MEK inhibition, no clinical trials, no literature, and a "Hold" recommendation. This report instead covers the next-ranked, evidence-backed prediction: non-cutaneous melanoma.
One-Sentence Summary
Trametinib is a MEK1/2 inhibitor established (in combination with the BRAF inhibitor dabrafenib) for BRAF V600E/K-mutant cutaneous melanoma. The TxGNN model additionally predicts activity in Non-Cutaneous Melanoma (mucosal, acral, uveal, and ocular/conjunctival subtypes), with 50 clinical trials identified in the underlying BRAF-mutant melanoma evidence base and 3 supporting case-level publications specific to non-cutaneous (ocular/mucosal) sites.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | BRAF V600E/K-mutant cutaneous melanoma (established combination use with dabrafenib; not derivable from Finland regulatory record, see below) |
| Predicted New Indication | Non-Cutaneous Melanoma |
| TxGNN Prediction Score | 99.30% |
| Evidence Level | L1 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Trametinib is a MEK1/2 inhibitor acting downstream in the RAS-RAF-MEK-ERK signalling pathway. In combination with the BRAF inhibitor dabrafenib, it is an established treatment for BRAF V600E/K mutation-positive melanoma, and this combination has been studied and approved primarily in cutaneous melanoma populations.
Non-cutaneous melanoma — encompassing mucosal, acral, uveal, and ocular/conjunctival subtypes — arises from the same melanocyte lineage but carries a lower BRAF V600 mutation prevalence (roughly 15–20% in acral melanoma, versus 50–60% in cutaneous superficial spreading melanoma). Critically, within the BRAF-mutant-positive subgroup of these non-cutaneous subtypes, the driving oncogenic mechanism is identical to cutaneous disease, so MEK inhibition remains mechanistically applicable.
Supporting this, case reports of BRAF-mutant conjunctival and lacrimal sac melanoma (ocular/mucosal, i.e. non-cutaneous) describe clinical responses to combined BRAF/MEK inhibition, and a dedicated Phase 2 trial (NCT02083354) specifically enrolled both acral and cutaneous BRAF V600-mutant melanoma patients under a shared dabrafenib + trametinib regimen. The prediction is therefore best framed as "effective in the BRAF-mutant-positive fraction of non-cutaneous melanoma," not the full non-cutaneous population indiscriminately.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04961619 | N/A | Completed | 39 | Real-world observational cohort of adjuvant dabrafenib + trametinib in completely resected high-risk Stage III melanoma (Turkey) |
| NCT02224781 | Phase 3 | Active, not recruiting | 267 | DREAMseq: sequencing of immunotherapy vs. dabrafenib+trametinib in unresectable/metastatic BRAF V600-mutant Stage III-IV melanoma |
| NCT02645149 | Phase 2 | Completed | 216 | Molecular profiling with matched targeted therapy in BRAF/NRAS wild-type and mutant advanced/metastatic melanoma |
| NCT02065063 | Phase 1 | Completed | 28 | Dose-escalation of trametinib + palbociclib (CDK4/6 inhibitor) in solid tumours including melanoma |
| NCT01940809 | Phase 1 | Terminated | 15 | Sequential BRAF-MEK inhibition with CTLA-4/PD-1 blockade, immune biomarker focus, in BRAF-mutant melanoma |
| NCT03979651 | N/A | Completed | 29 | Trametinib + hydroxychloroquine (autophagy inhibition) in NRAS-mutant melanoma |
| NCT04949113 | Phase 3 | Active, not recruiting | 423 | NADINA: neoadjuvant ipilimumab+nivolumab vs. standard adjuvant nivolumab in Stage III melanoma (dabrafenib+trametinib as reference standard arm) |
| NCT05668585 | Phase 1 | Completed | 89 | Safety/tolerability of CFT1946 alone and combined with trametinib in BRAF V600-mutant solid tumours |
| NCT05275374 | Phase 1/2 | Not yet recruiting | 221 | XP-102 ± trametinib in BRAF V600-mutant advanced solid tumours (melanoma, colorectal, NSCLC, thyroid) |
| NCT04547946 | N/A | Completed | 3 | Quality-of-life assessment of adjuvant dabrafenib+trametinib in melanoma (Portugal, real-world) |
Note: none of the above trials specifically restrict enrollment to non-cutaneous melanoma subtypes; NCT02083354 (see acral lentiginous melanoma sub-analysis) is the only identified trial explicitly including a non-cutaneous (acral) arm alongside cutaneous melanoma.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27893585 | 2017 | Case Report | Ophthalmic Plastic and Reconstructive Surgery | Conjunctival melanoma harbouring BRAF V600E mutation responsive to systemic BRAF/MEK inhibition |
| 31361915 | 2020 | Case Report | Clinical and Experimental Dermatology | Two cases of BRAF-mutated bulbar conjunctival (epithelioid-type) melanoma; one treated with a BRAF inhibitor for metastatic disease |
| 31747798 | 2019 | Case Report | Journal of Investigative Medicine High Impact Case Reports | Lacrimal sac malignant melanoma case and review of 15 Japanese patients |
Finland Market Information
Trametinib currently holds no marketing authorizations on file (total_licenses: 0, market_status: 未上市). No dosage form or product-level data is available to summarize.
Cytotoxicity (Antineoplastic Drug)
Trametinib is antineoplastic (MEK inhibitor used in BRAF-mutant melanoma), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (MEK1/2 inhibitor; not a conventional cytotoxic agent) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data were retrievable at this data cutoff (DDI query status: not found).
Flag: the evidence pack records a Blocking-severity data gap (DG001) — the TFDA/package-insert warnings and contraindications for trametinib have not yet been retrieved. This blocks completion of the S1 safety pre-assessment stage and should be resolved before any Go decision.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The BRAF-MEK inhibition mechanism is well-validated in BRAF-mutant melanoma broadly (L1 evidence, multiple completed/active Phase 2-3 trials), and case-level evidence supports activity in BRAF-mutant non-cutaneous (ocular/mucosal) melanoma specifically. However, no trial in the evidence base enrolls non-cutaneous melanoma as a primary, subtype-defined population, and BRAF mutation prevalence is markedly lower in non-cutaneous subtypes, so efficacy should be assumed only in BRAF-mutant-positive patients pending dedicated confirmation.
To proceed, the following is needed:
- Resolve the Blocking data gap (DG001): TFDA/package-insert warnings, contraindications, and DDI profile
- Confirm mechanism-of-action detail via DrugBank (DG002) to support a fuller mechanistic-relevance assessment
- Subtype-specific (mucosal/acral/uveal) trial data with BRAF-mutation stratification, since current trials pool cutaneous and non-cutaneous patients
- Finland/EU regulatory pathway assessment, given the drug currently holds no local marketing authorization
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.